Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CYP51A1-mediated alkaliptosis resistance is a targetable vulnerability in pancreatic cancer

ABSTRACT:

Alkaliptosis, a pH-dependent form of regulated cell death characterized by impaired lysosomal function and lethal alkalinization, holds promise as a target for cancer therapy. Here, we utilize mass spectrometry-based drug target, transcriptomic screens, and lipid metabolomics to explore the metabolic mechanisms underlying alkaliptosis. We reveal CYP51A1, a gene involved in cholesterol synthesis, as a key suppressor of alkaliptosis in pancreatic cancer cells. Inducing alkaliptosis leads to a decrease in endoplasmic reticulum cholesterol levels, subsequently activating SREBF2, a transcription factor responsible for controlling the expression of genes involved in cholesterol biosynthesis. Specifically, SREBF2-driven upregulation of CYP51A1 prevents cholesterol accumulation within lysosomes, leading to TMEM175-dependent lysosomal proton efflux, ultimately resulting in the inhibition of alkaliptosis.

PDAC-SW1990 cell line analysis is reported in the current study MTBLS9288.

PDAC-PANC1 cell line analysis is reported in MTBLS9283.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase

PROVIDER: MTBLS9288 | MetaboLights | 2025-02-28

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	sw1990_12h_1_N.mzML	Mzml
	sw1990_12h_1_P.mzML	Mzml
	sw1990_12h_2_N.mzML	Mzml
	sw1990_12h_2_P.mzML	Mzml
	sw1990_12h_3_N.mzML	Mzml

Items per page:

1 - 5 of 30

Similar Datasets

CYP51A1-mediated alkaliptosis resistance is a targetable vulnerability in pancreatic cancer

Project description:Alkaliptosis, a pH-dependent form of regulated cell death characterized by impaired lysosomal function and lethal alkalinization, holds promise as a target for cancer therapy. Here, we utilize mass spectrometry-based drug target, transcriptomic screens and lipid metabolomics to explore the metabolic mechanisms underlying alkaliptosis. We reveal CYP51A1, a gene involved in cholesterol synthesis, as a key suppressor of alkaliptosis in pancreatic cancer cells. Inducing alkaliptosis leads to a decrease in endoplasmic reticulum cholesterol levels, subsequently activating SREBF2, a transcription factor responsible for controlling the expression of genes involved in cholesterol biosynthesis. Specifically, SREBF2-driven upregulation of CYP51A1 prevents cholesterol accumulation within lysosomes, leading to TMEM175-dependent lysosomal proton efflux, ultimately resulting in the inhibition of alkaliptosis. In animal models, including xenografts, orthotopic and patient-derived models, the genetic or pharmacological inhibition of CYP51A1 enhances the effectiveness of JTC801 in suppressing pancreatic tumors. These findings demonstrate the key role of the CYP51A1-dependent lysosomal pathway in inhibiting alkaliptosis and highlight its potential as a targetable vulnerability in pancreatic cancer. PDAC-PANC1 cell line analysis is reported in the current study <a href='https://www.ebi.ac.uk/metabolights/MTBLS9283' rel='noopener noreferrer' target='_blank'>MTBLS9283</a>.PDAC-SW1990 cell line analysis is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS9288' rel='noopener noreferrer' target='_blank'>MTBLS9288</a>.

2025-02-28 | MTBLS9283 | MetaboLights

ESCRT-I controls lysosomal membrane protein homeostasis and restricts MCOLN1-dependent TFEB/TFE3 signaling.

Project description:Within the endolysosomal pathway in mammalian cells, ESCRT complexes facilitate degradation of membrane proteins from limiting membranes of late endosomes. Recent studies revealed that yeast ESCRT proteins also sort for degradation, ubiquitinated proteins from vacuolar membrane. However, whether mammalian ESCRTs perform similar function at lysosomes remained unknown. Here, we studied the involvement of mammalian ESCRT-I in maintaining lysosomal membrane homeostasis and its implication in lysosome-related signaling. We show that ESCRT-I restricts the size of lysosomes and promotes degradation of lysosomal Ca2+ channel, MCOLN1 protein. ESCRT-I depletion induced transcriptional response related to MiT-TFE signaling and cholesterol biosynthesis, pointing to lysosomal dysfunction. The lack of ESCRT-I promoted abnormal cholesterol accumulation on lysosomes and activated TFEB/TFE3 transcription factors in Ca2+-MCOLN1-dependent, but lipid-independent manner. Hence, our study provides evidence that ESCRT-I maintains lysosomal homeostasis and elucidates MiT-TFE regulatory mechanism activated in response to ESCRT-I deprivation

2022-03-28 | GSE178665 | GEO

Peripheral positioning of lysosomes supports melanoma aggressiveness

Project description:Emerging evidences suggest that both function and position of organelles are pivotal for tumor cell dissemination. Among them, lysosomes stand out as they integrate metabolic sensing with gene regulation and secretion of proteases. Yet, how lysosomes function is linked to their position and thereby control metastatic progression remains elusive. Here, we analyzed lysosome subcellular distribution in micropatterned patient-derived melanoma cells and found that lysosome spreading scales with their aggressiveness. Peripheral lysosomes promote invadopodia-based matrix degradation and invasion of melanoma cells which is directly linked to their lysosomal and cell transcriptional programs. When controlling lysosomal positioning using chemo-genetical heterodimerization in melanoma cells, we demonstrated that perinuclear clustering impairs lysosomal secretion, matrix degradation and invasion. Impairing lysosomal spreading in a zebrafish metastasis model significantly reduces invasive outgrowth. Our study provides a mechanistic demonstration that lysosomal positioning controls cell invasion, illustrating the importance of organelle adaptation in carcinogenesis.

2023-07-31 | E-MTAB-13165 | biostudies-arrayexpress

DOCK8 is a Novel Regulator of Lysosome Mediated Pancreatic Cancer Invasion

Project description:Amplified lysosome activity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) orchestrated by oncogenic KRAS that mediates tumor progression and metastasis, though the mechanisms underlying this phenomenon remain unclear. Using comparative proteomics, we found that oncogenic KRAS significantly enriches levels of the guanine nucleotide exchange factor (GEF) DOCK8 on lysosomes. Surprisingly, we found that DOCK8 is aberrantly expressed in a subset of PDAC where it promotes cell invasion and proliferation. Further, DOCK8 associates with lysosomes and regulates lysosomal morphology and motility. DOCK8 promotes actin polymerization at the surface of lysosomes, while increasing the levels and proteolytic activity of the lysosomal protease cathepsin B. Depletion of DOCK8 significantly reduces extracellular matrix degradation and impairs the invasive capacity of PDAC cells. Further, CRISPR-based knockout of DOCK8 dramatically reduces tumor size and metastasis in vivo. Together, these findings implicate ectopic expression of DOCK8 as a key driver of KRAS-driven lysosomal regulation, tumor progression, and metastasis.

2023-01-10 | MSV000091036 | MassIVE

Gene expression of zebrafish larvae upon treating with lalistat or U18666A

Project description:To test if HIF pathway is regulated by lipids in zebrafish larvae, we have employed whole genome microarray expression profiling as a discovery platform to identify induced genes upon lalistat or U18666A treatment. Lalistat is a specific inhibitor for lysosomal acid lipase (LAL), which is required for break down triglyceride or cholesterol ester to release free fatty acids. U18666A is a specific inhibitor for NPC, which is required for export free cholesterol oout of lysosomes.

2019-04-07 | GSE129434 | GEO

Proteomic analysis of bone-marrow derived macrophages from NPC1 KO mice

Project description:Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder mainly driven by mutations in NPC1 gene, causing lipid accumulation within late endosomes/lysosomes, and resulting in progressive neurodegeneration. To study the effect of NPC1 deficiency on the innate immune system, we performed proteomics on bone-marrow derived macrophages (BMDMs) of NPC1 KO and WT mice. Without further treatment or activation, BMDMs of NPC1 KO mice showed alterations mainly related to cholesterol metabolism, which is in line with the intracellular cholesterol transport function of NPC1.

2024-12-05 | PXD056249 | Pride

Effect of SPNS1 on lipid metabolism in mice

Project description:Accumulation of sphingolipids, especially sphingosines, in the lysosomes is attributed to the pathogenesis of several lysosomal storage diseases. In searching for a lysosomal protein that mediates the release of sphingosines, we identified SPNS1 which shares the highest homology to SPNS2, a sphingosine-1-phosphate (S1P) transporter. We generated knockout cells and mice for Spns1 and employed lipidomics and metabolomics to identify SPNS1 ligands. We found that knockouts of Spns1 resulted in the accumulation of sphingolipids including sphingosines in embryonic brains and cell lines. These results suggest that deficiency of SPNS1 affects the clearance of sphingolipids in lysosomes. Biochemical assays demonstrated that sphingosines released from lysosomes required SPNS1. Postnatal deletion of Spns1 in mice causes lipid accumulation in the lysosomes and pathological conditions that are reminiscent of sphingolipid lysosomal storage diseases. These results reveal a critical molecular role of SPNS1 as a transporter for lysosphingolipids and lysoglyerophospholipids from the lysosomes and link its physiological roles with lysosomal storage diseases.

2024-06-12 | GSE240323 | GEO

Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer [CRISPR screen]

Project description:Pancreatic ductal adenocarcinoma (PDAC) subsists in a nutrient-deregulated microenvironment, making it particularly susceptible to treatments that interfere with cancer metabolism. For example, PDAC utilizes and is dependent on high levels of autophagy and other lysosomal processes. Although targeting these pathways has shown potential in preclinical studies, progress has been hampered by the challenge of identifying and characterizing favorable targets for drug development6. Here, we characterize PIKfyve, a lipid kinase integral to lysosomal functioning, as a novel and targetable vulnerability in PDAC. In human patient and murine PDAC samples, we discovered that PIKFYVE is overexpressed in PDAC cells compared to adjacent normal cells. Employing a genetically engineered mouse model, we established the essential role of PIKfyve in PDAC progression. Further, through comprehensive metabolic analyses, we found that PIKfyve inhibition obligated PDAC to upregulate de novo lipid synthesis and specifically sphingolipid synthesis, a relationship previously undescribed. PIKfyve inhibition triggered a distinct lipogenic gene expression and metabolic program, creating a dependency on de novo lipid metabolism pathways, by upregulating genes such as FASN and ACACA. In PDAC, the KRAS-MAPK signaling pathway is a primary driver of de novo lipid synthesis, specifically enhancing FASN and ACACA levels. Accordingly, the simultaneous targeting of PIKfyve and KRAS-MAPK resulted in the elimination of tumor burden in a syngeneic orthotopic model and tumor regression in a xenograft model of PDAC. Taken together, these studies suggest that disrupting lipid metabolism through PIKfyve inhibition induces synthetic lethality in conjunction with KRAS-MAPK-directed therapies for PDAC.

2025-02-19 | GSE277831 | GEO

Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer [ChIP-seq]

2025-02-19 | GSE277830 | GEO

MALT1 paracaspase controls cholesterol homeostasis in glioblastoma stem-like cells through lysosome proteome shaping

Project description:Glioblastoma stem-like cells (GSCs) compose a tumor-initiating and propagating-population, remarkably vulnerable to any variation in the stability and integrity of the endolysomal compartment. Previous work showed that the expression and activity of the paracaspase MALT1 control GSC viability via lysosomal abundance. However, the underlying mechanisms remain elusive. By combining RNAseq to quantitative proteomic analysis, we now report that MALT1 inhibition in patient-derived GSCs causes severe defects in the homeostasis of cholesterol, which aberrantly accumulated in lysosomes. This failure in cholesterol supply culminates in cell death and autophagy defects, which can be partially reverted by providing exogenous membrane-permeable cholesterol to GSCs. From a molecular standpoint, targeted lysosome proteome analysis unraveled that NPC1/2 lysosomal cholesterol transporters were exhausted when MALT1 is held in check. Accordingly, we found that hindering NPC1 and NPC2 phenocopies MALT1 inhibition. This supports the notion that GSC fitness relies on lysosomal cholesterol homeostasis.

2025-01-16 | PXD040862 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data